Open Label PK, PD and DDI of Dotinurad and Allopurinol in Gout Patients With Hyperuricemia
Status:
Recruiting
Trial end date:
2023-11-01
Target enrollment:
Participant gender:
Summary
A open label multi-center 3-period multidose, PK/PD and drug-drug interaction (DDI) study to
evaluate the pharmacokinetics (PK) and pharmacodynamics (PD) of 7 days of treatment with two
doses of dotinurad monotherapy, and to evaluate the effect of dotinurad, as monotherapy and
in combination with allopurinol, versus allopurinol monotherapy, on the PK of each, and to
assess the additive PD effects on serum uric acid and urinary urate excretion in U.S.
patients with gout and hyperuricemia